Sun Pharmaceuticals will acquire all of Organon's tradable shares in full cash at a price of $14 per share. The company's valuation of the transaction reached 11.75 billion US dollars. The deal has been approved by the boards of directors of Sun Pharmaceuticals and Organon. Sun Pharmaceuticals plans to fund the acquisition by combining its own working capital and bank financing commitments. The deal is expected to be completed in early 2027, and is subject to regular closing conditions such as regulatory approval and Organon shareholder voting.

Sun Pharmaceuticals will acquire all of Organon's tradable shares in full cash at a price of $14 per share. The company's valuation of the transaction reached 11.75 billion US dollars. The deal has been approved by the boards of directors of Sun Pharmaceuticals and Organon. Sun Pharmaceuticals plans to fund the acquisition by combining its own working capital and bank financing commitments. The deal is expected to be completed in early 2027, and is subject to regular closing conditions such as regulatory approval and Organon shareholder voting.